Y-mAbs Therapeutics YMAB

$ 10.38 2.72%

Quarterly report 2024-Q3
added 11-08-2024

Y-mAbs Therapeutics Balance Sheet 2011-2024 | YMAB

Annual Balance Sheet Y-mAbs Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-77.2 M	-104 M	-178 M	-111 M	-205 M	-148 M	-90.5 M	-16.9 M	-	-	-	-	-
Long Term Debt	517 K	899 K	1.85 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	902 K	868 K	1.78 M	1.97 M	516 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	6.68 M	3.88 M	2.27 M	2.05 M	2.22 M	-	-	-	-	-
Total Current Liabilities	20.1 M	28.3 M	27.9 M	19.5 M	13.6 M	9.12 M	-	-	-	-	-	-	-
Total Liabilities	26.9 M	32.2 M	32.7 M	26.2 M	17.5 M	11.4 M	9.98 M	5.2 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-457 M	-436 M	-340 M	-285 M	-166 M	-84.8 M	-41.6 M	-22.4 M	-	-	-	-	-
Total Assets	128 M	141 M	213 M	132 M	216 M	152 M	92.1 M	17.3 M	-	-	-	-	-
Cash and Cash Equivalents	78.6 M	106 M	182 M	115 M	207 M	148 M	90.5 M	-	-	-	-	-	-
Book Value	101 M	109 M	180 M	106 M	199 M	141 M	82.2 M	12.1 M	-	-	-	-	-
Total Shareholders Equity	101 M	109 M	180 M	106 M	199 M	141 M	82.2 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Y-mAbs Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	299 K	432 K	293 K	517 K	725 K	416 K	629 K	899 K	1.02 M	1.3 M	1.6 M	1.85 M	654 K	988 K	1.52 M	2.01 M	2.01 M	2.01 M	2.01 M	1.71 M	1.71 M	1.71 M	1.71 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	28.5 M	48.7 M	24.1 M	26.9 M	28.7 M	27.7 M	29.6 M	32.2 M	36 M	33.8 M	33.6 M	32.7 M	29.1 M	25.2 M	22.7 M	26.2 M	26.2 M	26.2 M	26.2 M	17.5 M	17.5 M	17.5 M	17.5 M	11.4 M	11.4 M	11.4 M	11.4 M	9.98 M	9.98 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-480 M	-473 M	-464 M	-457 M	-456 M	-449 M	-442 M	-436 M	-437 M	-410 M	-369 M	-340 M	-304 M	-275 M	-252 M	-285 M	-285 M	-285 M	-285 M	-166 M	-166 M	-166 M	-166 M	-84.8 M	-84.8 M	-84.8 M	-84.8 M	-41.6 M	-41.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	121 M	144 M	123 M	128 M	129 M	132 M	137 M	141 M	144 M	165 M	191 M	213 M	240 M	259 M	275 M	132 M	132 M	132 M	132 M	216 M	216 M	216 M	216 M	152 M	152 M	152 M	152 M	92.1 M	92.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	68.1 M	77.8 M	75.7 M	78.6 M	86.6 M	87.9 M	92.6 M	106 M	115 M	134 M	157 M	182 M	216 M	234 M	252 M	115 M	115 M	115 M	115 M	207 M	207 M	207 M	207 M	148 M	148 M	148 M	148 M	90.5 M	90.5 M	-	-	16.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	92.4 M	95.3 M	99.2 M	101 M	100 M	105 M	108 M	109 M	108 M	131 M	157 M	180 M	211 M	234 M	252 M	106 M	106 M	106 M	106 M	199 M	199 M	199 M	199 M	141 M	141 M	141 M	141 M	82.2 M	82.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	92.4 M	95.3 M	99.2 M	101 M	100 M	105 M	108 M	109 M	108 M	131 M	157 M	180 M	211 M	234 M	252 M	106 M	106 M	106 M	106 M	199 M	199 M	199 M	199 M	141 M	141 M	141 M	141 M	82.2 M	82.2 M	-	-	12.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency